Chromatin structure predicts epigenetic therapy responsiveness in sarcoma

Molecular Cancer Therapeutics

Volumn 10, Issue 2, 2011, Pages 313-324

  Mills, Joslyn ^a   Hricik, Todd ^a   Siddiqi, Sara ^a   Matushansky, Igor ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BELINOSTAT; CYCLIN DEPENDENT KINASE INHIBITOR 1; PANOBINOSTAT; ROMIDEPSIN; VALPROIC ACID; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER INHIBITION; CHROMATIN STRUCTURE; CONTROLLED STUDY; DRUG POTENTIATION; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; SARCOMA; SARCOMA CELL; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN; CLUSTER ANALYSIS; DRUG SYNERGISM; ENZYME INHIBITORS; EPIGENOMICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, SCID; RANDOM ALLOCATION; SARCOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951818091     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0724     Document Type: Article

References (44)

1. Tuma RS. Epigenetic therapies move into new territory, but how exactly do they work? J Natl Cancer Inst 2009;101:1300-1.
2. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009;15:3970-7.
3. Baron MH. Embryonic origins of mammalian hematopoiesis. Exp Hematol 2003;31:1160-9. (Pubitemid 37510020)
4. Matushansky I, Maki RG. Mechanisms of sarcomagenesis. Hematol/ Oncol Clin N Am 2005;19:427-49, v.
5. Matushansky I, Hernando E, Socci ND, Matos T, Mills J, Edgar MA, et al. A developmental model of sarcomagenesis defines a differentiation- based classification for liposarcomas. Am J Pathol 2008; 172:1069-80. (Pubitemid 351520003)
6. Matushansky I, Hernando E, Socci ND, Mills JE, Matos TA, Edgar MA, et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 2007;117:3248-57. (Pubitemid 350096982)
7. Cironi L, Provero P, Riggi N, Janiszewska M, Suva D, Suva ML, et al. Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. PLoS One 2009;4:e7904.
8. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007;11:421-9. (Pubitemid 46680428)
9. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008;112:1570-80.
10. Kumar C, Purandare AV, Lee FY, Lorenzi MV. Kinase drug discovery approaches in chronic myeloproliferative disorders. Oncogene 2009;28:2305-13.
11. de Bruijn DR, Allander SV, van Dijk AH, Willemse MP, Thijssen J, van Groningen JJ, et al. The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res 2006;66:9474-82. (Pubitemid 44623645)
12. Sadikovic B, Yoshimoto M, Al-Romaih K, Maire G, Zielenska M, Squire JA. In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS One 2008;3:e2834.
13. Xing D, Scangas G, Nitta M, He L, Xu X, Ioffe YJ, et al. A role for BRCA1 in uterine leiomyosarcoma. Cancer Res 2009;69:8231-5.
14. Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, Hauptmann S, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007;46:865-71. (Pubitemid 47549772)
15. Takahira T, Oda Y, Tamiya S, Yamamoto H, Kawaguchi K, Kobayashi C, et al. Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma. Cancer Sci 2004;95:651-5. (Pubitemid 39255812)
16. Lynch CA, Tycko B, Bestor TH, Walsh CP. Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation. Mol Can 2002;1:2.
17. Al-Romaih K, Sadikovic B, Yoshimoto M, Wang Y, Zielenska M, Squire JA. Decitabine-induced demethylation of 5′ CpG island in GADD45A leads to apoptosis in osteosarcoma cells. Neoplasia 2008;10:471-80.
18. Numoto K, Yoshida A, Sugihara S, Kunisada T, Morimoto Y, Yoneda Y, et al. Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2′-deoxycytidine against synovial sarcoma cell lines. J Cancer Res Clin Oncol 2009 Jul 4. [Epub ahead of print].
19. Hrzenjak A, Kremser ML, Strohmeier B, Moinfar F, Zatloukal K, Denk H. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol 2008;216:495-504.
20. Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 2003;9:5749-55. (Pubitemid 37499499)
21. Liu S, Cheng H, Kwan W, Lubieniecka JM, Nielsen TO. Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. Mol Cancer Ther 2008;7:1751-61.
22. Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, et al. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer 2005;116:784-92. (Pubitemid 41099711)
23. Sonnemann J, Dreyer L, Hartwig M, Palani CD, Hong le TT, Klier U, et al. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol 2007;133:847-58. (Pubitemid 350218911)
24. Yamamoto S, Tanaka K, Sakimura R, Okada T, Nakamura T, Li Y, et al. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy- associated cell death in chondrosarcoma cell lines. Anticancer Res 2008;28:1585-91. (Pubitemid 351892934)
25. Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006;6:2.
26. Ecke I, Petry F, Rosenberger A, Tauber S, Monkemeyer S, Hess I, et al. Antitumor effects of a combined 5-aza-2′-deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res 2009;69:887-95.
27. Hurtubise A, Bernstein ML, Momparler RL. Preclinical evaluation of the antineoplastic action of 5-aza-2′-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. Cancer Cell Int 2008;8:16.
28. Mills J, Matos T, Charytonowicz E, Hricik T, Castillo-Martin M, Remotti F, et al. Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivo. Hum Cell 2009;22:85-93.
29. Matushansky I, Radparvar F, Skoultchi AI. Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1. Proc Natl Acad Sci U S A 2000;97:14317-22. (Pubitemid 32016573)
30. Mukhopadhyay D, Houchen CW, Kennedy S, Dieckgraefe BK, Anant S. Coupled mRNA stabilization and translational silencing of cyclooxygenase- 2 by a novel RNA binding protein, CUGBP2. Mol Cell 2003;11:113-26. (Pubitemid 36126595)
31. de Toledo M, Senic-Matuglia F, Salamero J, Uze G, Comunale F, Fort P, et al. The GTP/GDP cycling of rho GTPase TCL is an essential regulator of the early endocytic pathway. Mol Biol Cell 2003;14:4846-56. (Pubitemid 37484801)
32. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000;97:10014-9.
33. Segal NH, Pavlidis P, Antonescu CR, Maki RG, Noble WS, DeSantis D, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 2003;163:691-700. (Pubitemid 36909430)
34. Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009;41:199-213.
35. Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010;62:18-34.
36. Chou TC. Preclinical versus clinical drug combination studies. Leuk Lymphoma 2008;49:2059-80.
37. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
38. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
39. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007;13:748-53. (Pubitemid 46889749)
40. Vignal E, De Toledo M, Comunale F, Ladopoulou A, Gauthier-Rouviere C, Blangy A, et al. Characterization of TCL, a new GTPase of the rho family related to TC10 and Ccdc42. J Biol Chem 2000;275:36457-64.
41. Dembowski JA, Grabowski PJ. The CUGBP2 splicing factor regulates an ensemble of branchpoints from perimeter binding sites with implications for autoregulation. PLoS Genet 2009;5:e1000595.
42. Siddiqi S, Mills J, Matushansky I. Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas. Curr Stem Cell Res Ther 2010;5:63-73.
43. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009;8:1409-20.
44. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92. (Pubitemid 46273572)